Abbott Laboratories $ABT Holdings Decreased by Clark & Stuart Inc

Clark & Stuart Inc lessened its stake in Abbott Laboratories (NYSE:ABT) by 20.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,381 shares of the healthcare product maker’s stock after selling 3,909 shares during the period. Abbott Laboratories accounts for 1.6% of Clark & Stuart Inc’s portfolio, making the stock its 20th biggest holding. Clark & Stuart Inc’s holdings in Abbott Laboratories were worth $2,092,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories during the first quarter valued at approximately $27,000. Abound Financial LLC bought a new position in Abbott Laboratories during the 1st quarter valued at $28,000. Elequin Capital LP acquired a new position in shares of Abbott Laboratories during the 1st quarter valued at $30,000. JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories in the 1st quarter worth $32,000. Finally, Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories in the first quarter valued at $33,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Price Performance

ABT stock opened at $133.63 on Tuesday. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The firm has a 50-day moving average of $132.08 and a two-hundred day moving average of $131.44. The firm has a market capitalization of $232.58 billion, a PE ratio of 16.75, a P/E/G ratio of 2.55 and a beta of 0.69. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the previous year, the business earned $1.14 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. The Goldman Sachs Group lifted their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research report on Friday, July 18th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Morgan Stanley increased their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Finally, Wells Fargo & Company decreased their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $145.39.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.